Vertex Pharmaceuticals (VRTX) Expected to Announce Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is anticipated to release its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Vertex Pharmaceuticals to post earnings of $4.24 per share and revenue of $2.85 billion for the quarter. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, analysts expect Vertex Pharmaceuticals to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

VRTX stock traded up $6.00 during mid-day trading on Wednesday, reaching $509.50. The company's stock had a trading volume of 1,445,335 shares, compared to its average volume of 1,339,506. The stock has a market cap of $130.98 billion, a PE ratio of -231.59, a P/E/G ratio of 2.11 and a beta of 0.50. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company's 50 day moving average is $490.74 and its two-hundred day moving average is $466.65.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VRTX. BMO Capital Markets set a $545.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Scotiabank increased their price objective on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research report on Tuesday, February 11th. Barclays increased their price objective on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 11th. Piper Sandler lowered their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. Finally, Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a research report on Thursday, January 30th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $514.91.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the company's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the sale, the executive vice president now directly owns 64,021 shares of the company's stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,315 shares of company stock valued at $2,121,012 in the last three months. 0.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

An institutional investor recently raised its position in Vertex Pharmaceuticals stock. Brighton Jones LLC increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,427 shares of the pharmaceutical company's stock after purchasing an additional 579 shares during the quarter. Brighton Jones LLC's holdings in Vertex Pharmaceuticals were worth $1,783,000 as of its most recent filing with the SEC. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.